Regenxbio IncNASDAQ:RGNX
- LAST PRICE9.1800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots9.0000/ 4
- Ask / Lots9.5000/ 1
- Open / Previous Close--- / 9.1800
- Day Range---
- 52 Week Range
- Volume57
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 14935 | 9.67 |
| 09:33 ET | 4457 | 9.37 |
| 09:35 ET | 4213 | 9.59 |
| 09:37 ET | 700 | 9.44 |
| 09:39 ET | 100 | 9.535 |
| 09:42 ET | 2300 | 9.54 |
| 09:44 ET | 200 | 9.505 |
| 09:46 ET | 3697 | 9.68 |
| 09:48 ET | 1025 | 9.62 |
| 09:50 ET | 857 | 9.605 |
| 09:51 ET | 1050 | 9.57 |
| 09:53 ET | 200 | 9.5965 |
| 09:55 ET | 564 | 9.57 |
| 10:02 ET | 200 | 9.52 |
| 10:04 ET | 6900 | 9.5 |
| 10:06 ET | 2266 | 9.43 |
| 10:08 ET | 400 | 9.375 |
| 10:09 ET | 1485 | 9.4 |
| 10:11 ET | 1000 | 9.395 |
| 10:13 ET | 3509 | 9.419362 |
| 10:15 ET | 7152 | 9.4 |
| 10:18 ET | 618 | 9.43 |
| 10:20 ET | 2046 | 9.4699 |
| 10:22 ET | 300 | 9.435 |
| 10:24 ET | 100 | 9.44 |
| 10:26 ET | 850 | 9.44 |
| 10:27 ET | 876 | 9.39 |
| 10:29 ET | 200 | 9.4 |
| 10:31 ET | 18359 | 9.39 |
| 10:33 ET | 7568 | 9.3 |
| 10:36 ET | 15093 | 9.2801 |
| 10:38 ET | 4100 | 9.29 |
| 10:40 ET | 700 | 9.2859 |
| 10:42 ET | 200 | 9.26 |
| 10:44 ET | 900 | 9.275 |
| 10:45 ET | 1466 | 9.29 |
| 10:47 ET | 1200 | 9.29 |
| 10:49 ET | 4171 | 9.31 |
| 10:51 ET | 300 | 9.32 |
| 10:54 ET | 2300 | 9.3 |
| 10:56 ET | 100 | 9.3 |
| 10:58 ET | 450 | 9.3 |
| 11:00 ET | 700 | 9.3 |
| 11:02 ET | 200 | 9.3 |
| 11:03 ET | 5838 | 9.256 |
| 11:05 ET | 3171 | 9.205 |
| 11:07 ET | 2703 | 9.205 |
| 11:09 ET | 5972 | 9.195 |
| 11:12 ET | 2318 | 9.19 |
| 11:14 ET | 616 | 9.185 |
| 11:16 ET | 1442 | 9.23 |
| 11:18 ET | 3963 | 9.2 |
| 11:20 ET | 4659 | 9.21 |
| 11:21 ET | 8705 | 9.175 |
| 11:23 ET | 2675 | 9.17 |
| 11:25 ET | 741 | 9.19 |
| 11:27 ET | 833 | 9.1866 |
| 11:30 ET | 2322 | 9.26 |
| 11:32 ET | 1148 | 9.255 |
| 11:34 ET | 5912 | 9.2 |
| 11:36 ET | 1807 | 9.22 |
| 11:38 ET | 1464 | 9.2 |
| 11:39 ET | 700 | 9.215 |
| 11:41 ET | 1400 | 9.213 |
| 11:43 ET | 1300 | 9.205 |
| 11:45 ET | 4513 | 9.17 |
| 11:48 ET | 5138 | 9.13 |
| 11:50 ET | 200 | 9.125 |
| 11:52 ET | 2513 | 9.15 |
| 11:54 ET | 743 | 9.16 |
| 11:56 ET | 8632 | 9.26 |
| 11:57 ET | 1719 | 9.2408 |
| 11:59 ET | 1732 | 9.25 |
| 12:01 ET | 300 | 9.25 |
| 12:03 ET | 100 | 9.25 |
| 12:06 ET | 600 | 9.22 |
| 12:08 ET | 500 | 9.225 |
| 12:10 ET | 2565 | 9.235 |
| 12:12 ET | 1387 | 9.249 |
| 12:14 ET | 865 | 9.245 |
| 12:15 ET | 2171 | 9.235 |
| 12:17 ET | 1100 | 9.235 |
| 12:19 ET | 700 | 9.235 |
| 12:21 ET | 946 | 9.2375 |
| 12:24 ET | 100 | 9.26 |
| 12:26 ET | 913 | 9.245 |
| 12:28 ET | 465 | 9.26 |
| 12:30 ET | 704 | 9.255 |
| 12:32 ET | 2200 | 9.2875 |
| 12:33 ET | 973 | 9.25 |
| 12:35 ET | 503 | 9.265 |
| 12:37 ET | 929 | 9.27 |
| 12:39 ET | 1002 | 9.28 |
| 12:42 ET | 800 | 9.29 |
| 12:44 ET | 500 | 9.3 |
| 12:46 ET | 2478 | 9.3 |
| 12:48 ET | 2115 | 9.31 |
| 12:50 ET | 200 | 9.3 |
| 12:51 ET | 1443 | 9.3 |
| 12:53 ET | 433 | 9.295 |
| 12:57 ET | 3358 | 9.36 |
| 01:00 ET | 646 | 9.35 |
| 01:02 ET | 675 | 9.355 |
| 01:04 ET | 6514 | 9.37 |
| 01:06 ET | 200 | 9.37 |
| 01:08 ET | 1366 | 9.35 |
| 01:09 ET | 400 | 9.34 |
| 01:11 ET | 100 | 9.34 |
| 01:13 ET | 850 | 9.36 |
| 01:15 ET | 200 | 9.37 |
| 01:18 ET | 1124 | 9.345 |
| 01:20 ET | 100 | 9.345 |
| 01:24 ET | 900 | 9.36 |
| 01:26 ET | 2851 | 9.36 |
| 01:27 ET | 1200 | 9.35 |
| 01:29 ET | 900 | 9.345 |
| 01:31 ET | 909 | 9.37 |
| 01:33 ET | 218 | 9.38 |
| 01:36 ET | 100 | 9.38 |
| 01:38 ET | 300 | 9.37 |
| 01:40 ET | 1097 | 9.35 |
| 01:42 ET | 300 | 9.35 |
| 01:44 ET | 16687 | 9.365 |
| 01:45 ET | 243 | 9.35 |
| 01:47 ET | 2577 | 9.34 |
| 01:49 ET | 1297 | 9.335 |
| 01:51 ET | 1636 | 9.32 |
| 01:54 ET | 6061 | 9.25 |
| 01:56 ET | 1962 | 9.24 |
| 01:58 ET | 1520 | 9.26 |
| 02:00 ET | 260 | 9.26 |
| 02:02 ET | 1777 | 9.24 |
| 02:03 ET | 1184 | 9.26 |
| 02:05 ET | 200 | 9.25 |
| 02:07 ET | 900 | 9.24 |
| 02:09 ET | 600 | 9.24 |
| 02:12 ET | 2200 | 9.23 |
| 02:14 ET | 400 | 9.23 |
| 02:16 ET | 2523 | 9.204 |
| 02:18 ET | 1427 | 9.2 |
| 02:20 ET | 1350 | 9.2 |
| 02:21 ET | 800 | 9.205 |
| 02:23 ET | 2954 | 9.2 |
| 02:25 ET | 1023 | 9.21 |
| 02:30 ET | 1977 | 9.2 |
| 02:32 ET | 1422 | 9.2 |
| 02:34 ET | 1629 | 9.21 |
| 02:36 ET | 1877 | 9.2 |
| 02:38 ET | 1912 | 9.2 |
| 02:41 ET | 5650 | 9.18 |
| 02:43 ET | 5496 | 9.16 |
| 02:45 ET | 4992 | 9.145 |
| 02:48 ET | 840 | 9.17 |
| 02:50 ET | 4084 | 9.115 |
| 02:52 ET | 1647 | 9.14 |
| 02:54 ET | 1600 | 9.13 |
| 02:56 ET | 1000 | 9.13 |
| 02:57 ET | 568 | 9.13 |
| 02:59 ET | 3100 | 9.11 |
| 03:01 ET | 4161 | 9.12 |
| 03:03 ET | 400 | 9.11 |
| 03:06 ET | 2352 | 9.115 |
| 03:08 ET | 3126 | 9.16 |
| 03:10 ET | 1182 | 9.17 |
| 03:12 ET | 3166 | 9.18 |
| 03:14 ET | 315 | 9.18 |
| 03:15 ET | 2655 | 9.16 |
| 03:17 ET | 500 | 9.16 |
| 03:19 ET | 2527 | 9.21 |
| 03:21 ET | 950 | 9.21 |
| 03:24 ET | 12669 | 9.26 |
| 03:26 ET | 1260 | 9.25 |
| 03:28 ET | 743 | 9.26 |
| 03:30 ET | 5485 | 9.225 |
| 03:32 ET | 1604 | 9.225 |
| 03:33 ET | 4208 | 9.215 |
| 03:35 ET | 1964 | 9.215 |
| 03:37 ET | 4104 | 9.2 |
| 03:39 ET | 2357 | 9.2 |
| 03:42 ET | 2093 | 9.21 |
| 03:44 ET | 2149 | 9.185 |
| 03:46 ET | 3170 | 9.19 |
| 03:48 ET | 1348 | 9.19 |
| 03:50 ET | 4676 | 9.205 |
| 03:51 ET | 4411 | 9.2 |
| 03:53 ET | 6430 | 9.23 |
| 03:55 ET | 3526 | 9.195 |
| 03:57 ET | 21791 | 9.17 |
| 04:00 ET | 104362 | 9.18 |
Yesterday
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 7:01AM ET on Thursday Nov 21, 2024 by Dow Jones
7:01AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 20, 2024
DJ REGENXBIO Is Maintained at Buy by Chardan Capital, from 6:11AM ET on Wednesday Nov 20, 2024 by Dow Jones
6:11AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
DJ Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion, from 9:09AM ET on Monday Nov 18, 2024 by Dow Jones
9:09AM ET on Monday Nov 18, 2024 by Dow JonesREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE(R) TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA, from 7:05AM ET on Monday Nov 18, 2024 by Dow Jones
7:05AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ REGENXBIO Coverage Assumed by Morgan Stanley at Overweight, from 7:14AM ET on Friday Nov 15, 2024 by Dow Jones
7:14AM ET on Friday Nov 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 454.8M | -1.8x | --- |
Y-mAbs Therapeutics Inc | 452.4M | -18.7x | --- |
Urogen Pharma Ltd | 487.4M | -3.7x | --- |
Grail Inc | 550.4M | 0.0x | --- |
Alector Inc | 368.2M | -2.2x | --- |
Chromadex Corp | 582.8M | 403.1x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Kenneth Mills
- President, Chief Executive Officer, Director
- Curran Simpson
- Chief Financial Officer, Executive Vice President, Principal Accounting Officer
- Mitchell Chan
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
- Executive Vice President, Chief Legal Officer
- Patrick Christmas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $454.8M |
|---|---|
Revenue (TTM) | $84.3M |
Shares Outstanding | 49.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-5.03 |
Book Value | $7.08 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -291.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
